Campbell & CO Investment Adviser LLC Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT

Campbell & CO Investment Adviser LLC boosted its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 146.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,879 shares of the company’s stock after purchasing an additional 23,730 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Arcutis Biotherapeutics were worth $752,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AQR Capital Management LLC lifted its stake in shares of Arcutis Biotherapeutics by 21.4% in the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock worth $3,882,000 after purchasing an additional 43,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Arcutis Biotherapeutics by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock valued at $1,118,000 after buying an additional 2,063 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in Arcutis Biotherapeutics during the second quarter valued at approximately $217,000. LVW Advisors LLC raised its position in Arcutis Biotherapeutics by 21.4% in the second quarter. LVW Advisors LLC now owns 17,561 shares of the company’s stock worth $246,000 after acquiring an additional 3,095 shares during the period. Finally, Fishman Jay A Ltd. MI raised its position in Arcutis Biotherapeutics by 4.3% in the second quarter. Fishman Jay A Ltd. MI now owns 556,150 shares of the company’s stock worth $7,797,000 after acquiring an additional 23,000 shares during the period.

Insiders Place Their Bets

In related news, Director Sue-Jean Lin sold 25,272 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $30.78, for a total value of $777,872.16. Following the sale, the director directly owned 26,735 shares in the company, valued at approximately $822,903.30. The trade was a 48.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick Burnett sold 2,490 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $28.98, for a total value of $72,160.20. Following the transaction, the insider directly owned 94,120 shares of the company’s stock, valued at approximately $2,727,597.60. The trade was a 2.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 293,912 shares of company stock worth $7,885,305. 9.40% of the stock is owned by corporate insiders.

Arcutis Biotherapeutics Trading Up 0.1%

ARQT stock opened at $25.87 on Wednesday. Arcutis Biotherapeutics, Inc. has a 1-year low of $11.13 and a 1-year high of $31.77. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.50 and a quick ratio of 3.28. The company has a market capitalization of $3.17 billion, a price-to-earnings ratio of -71.86 and a beta of 1.71. The business has a 50 day simple moving average of $28.53 and a two-hundred day simple moving average of $21.62.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.16. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. The firm had revenue of $99.22 million for the quarter, compared to analysts’ expectations of $86.69 million. Research analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARQT has been the subject of a number of recent research reports. Needham & Company LLC boosted their price objective on shares of Arcutis Biotherapeutics from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Mizuho upped their price target on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group boosted their price objective on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.00.

Arcutis Biotherapeutics Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.